文献速递临床试验与 GCP流行病学与生物统计

贝派地酸治疗高胆固醇血症的疗效与安全性:系统综述与Meta分析

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2020-07-16

该系统综述与Meta分析纳入10项II/III期随机对照试验(n=3,788),评估贝派地酸对血脂和hsCRP的影响及安全性。结果显示贝派地酸显著降低总胆固醇、non-HDL-C、LDL-C等指标及hsCRP,但增加治疗中断、尿酸升高、肝酶升高和肌酸激酶升高的风险,同时降低新发或恶化糖尿病的风险。

要点

  • 贝派地酸显著降低LDL-C(MD -22.94%)、总胆固醇(MD -14.94%)和hsCRP(MD -27.03%)。
  • 贝派地酸增加治疗中断(OR 1.37)、尿酸升高(OR 3.55)、肝酶升高(OR 4.28)和肌酸激酶升高(OR 3.79)的风险。
  • 贝派地酸与新发或恶化糖尿病风险降低相关(OR 0.59)。

核心结论

  • 贝派地酸对血脂谱和hsCRP水平有有利影响,且安全性可接受。
  • 需要进一步设计良好的研究探索其长期安全性。

研究设计与样本

  • 系统综述与Meta分析,纳入10项II期和III期随机对照试验(n=3,788),共26个臂(活性臂n=2,460;对照臂n=1,328)。
  • 检索PubMed、Scopus、Google Scholar和Web of Science数据库,从建库至2019年8月5日,无语言限制。

主要发现

  • 贝派地酸显著降低总胆固醇(MD -14.94%;95% CI -17.31%, -12.57%;p < 0.001)。
  • 贝派地酸显著降低non-HDL-C(MD -18.17%;95% CI -21.14%, -15.19%;p < 0.001)和LDL-C(MD -22.94%;95% CI -26.63%, -19.25%;p < 0.001)。
  • 贝派地酸显著降低LDL颗粒数(MD -20.67%;95% CI -23.84%, -17.48%;p < 0.001)、载脂蛋白B(MD -15.18%;95% CI -17.41%, -12.95%;p < 0.001)、HDL-C(MD -5.83%;95% CI -6.14%, -5.52%;p < 0.001)、HDL颗粒数(MD -3.21%;95% CI -6.40%, -0.02%;p = 0.049)和hsCRP(MD -27.03%;95% CI -31.42%, -22.64%;p < 0.001)。
  • 贝派地酸未显著改变甘油三酯水平(MD -1.51%;95% CI -3.75%, 0.74%;p = 0.189)、VLDL颗粒数(MD 3.79%;95% CI -9.81%, 17.39%;p = 0.585)和载脂蛋白A-1(MD -1.83%;95% CI -5.23%, 1.56%;p = 0.290)。
  • 贝派地酸与治疗中断风险增加(OR 1.37;95% CI 1.06, 1.76;p = 0.015)、血清尿酸升高(OR 3.55;95% CI 1.03, 12.27;p = 0.045)、肝酶升高(OR 4.28;95% CI 1.34, 13.71;p = 0.014)和肌酸激酶升高(OR 3.79;95% CI 1.06, 13.51;p = 0.04)相关,并与新发或恶化糖尿病风险降低强相关(OR 0.59;95% CI 0.39, 0.90;p = 0.01)。

临床怎么用

  • 贝派地酸可用于高胆固醇血症患者的降脂治疗,尤其适用于需要进一步降低LDL-C的患者。
  • 使用贝派地酸时应监测尿酸、肝酶和肌酸激酶水平,并关注治疗中断风险。
  • 对于糖尿病风险较高的患者,贝派地酸可能具有降低新发或恶化糖尿病风险的额外获益。

局限性

  • Meta分析的主要局限性在于涉及的个体数量相对较少,且研究通常为短期或中期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. METHODS AND FINDINGS: We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-sensitivity C-reactive protein (hsCRP) serum concentration were expressed as mean differences (MDs) and 95% confidence intervals (CIs). For safety analyses, odds ratios (ORs) and 95% CIs were calculated using the Mantel-Haenszel method. Bempedoic acid significantly reduced total cholesterol (MD -14.94%; 95% CI -17.31%, -12.57%; p < 0.001), non-high-density lipoprotein cholesterol (MD -18.17%; 95% CI -21.14%, -15.19%; p < 0.001), low-density lipoprotein cholesterol (MD -22.94%; 95% CI -26.63%, -19.25%; p < 0.001), low-density lipoprotein particle number (MD -20.67%; 95% CI -23.84%, -17.48%; p < 0.001), apolipoprotein B (MD -15.18%; 95% CI -17.41%, -12.95%; p < 0.001), high-density lipoprotein cholesterol (MD -5.83%; 95% CI -6.14%, -5.52%; p < 0.001), high-density lipoprotein particle number (MD -3.21%; 95% CI -6.40%, -0.02%; p = 0.049), and hsCRP (MD -27.03%; 95% CI -31.42%, -22.64%; p < 0.001). Bempedoic acid did not significantly modify triglyceride level (MD -1.51%; 95% CI -3.75%, 0.74%; p = 0.189), very-low-density lipoprotein particle number (MD 3.79%; 95% CI -9.81%, 17.39%; p = 0.585), and apolipoprotein A-1 (MD -1.83%; 95% CI -5.23%, 1.56%; p = 0.290). Treatment with bempedoic acid was positively associated with an increased risk of discontinuation of treatment (OR 1.37; 95% CI 1.06, 1.76; p = 0.015), elevated serum uric acid (OR 3.55; 95% CI 1.03, 12.27; p = 0.045), elevated liver enzymes (OR 4.28; 95% CI 1.34, 13.71; p = 0.014), and elevated creatine kinase (OR 3.79; 95% CI 1.06, 13.51; p = 0.04), though it was strongly associated with a decreased risk of new onset or worsening diabetes (OR 0.59; 95% CI 0.39, 0.90; p = 0.01). The main limitation of this meta-analysis is related to the relatively small number of individuals involved in the studies, which were often short or middle term in length. CONCLUSIONS: Our results show that bempedoic acid has favorable effects on lipid profile and hsCRP levels and an acceptable safety profile. Further well-designed studies are needed to explore its longer-term safety.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Cicero AFG, Fogacci F, Hernandez AV, et al. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. PLoS Med. 2020. PMID: 32673317. doi:10.1371/journal.pmed.1003121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。